Search research articles
Contact Us
Filters
Showing results (141-150 of 209) with videos related to
Page
of 21
Sort By:
Thoracic Cancer
|
August 19, 2023
Predicting pathological response to neoadjuvant or conversion chemoimmunotherapy in stage IB-III non-small cell lung cancer patients using radiomic features
Nong Yang, Hai-Lin Yue, Bai-Hua Zhang, et al.
JTO Clinical and Research Reports
|
October 11, 2022
Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring <i>MET</i> Exon 14 Skipping Alterations
Shun Lu, Jian Fang, Xingya Li, et al.
The Oncologist
|
April 17, 2026
Characterization and Clinical Management of Adverse Events Following Treatment with Repotrectinib: A TRIDENT-1 Analysis
Alexander Drilon, Byoung Chul Cho, D Ross Camidge, et al.
The Oncologist
|
May 8, 2026
Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis
Alexander Drilon, Byoung Chul Cho, D Ross Camidge, et al.
The Lancet. Respiratory Medicine
|
June 24, 2021
Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study
Shun Lu, Jian Fang, Xingya Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 5, 2025
Quantitative and Dynamic ctDNA as a Biomarker of Response and Survival in Patients With Advanced Lung Squamous Cell Carcinoma Receiving Immunochemotherapy or Chemotherapy Alone
Fei Zhou, Jiao Zhang, Shengxiang Ren, et al.
International Journal of Cancer
|
September 19, 2022
First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis
Tianshu Liu, Yuxian Bai, Xiaoyan Lin, et al.
Chinese Medical Journal
|
February 19, 2025
Potential utility of albumin-bilirubin and body mass index-based logistic model to predict survival outcome in non-small cell lung cancer with liver metastasis treated with immune checkpoint inhibitors
Lianxi Song, Qinqin Xu, Ting Zhong, et al.
Nature Medicine
|
May 22, 2024
Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial
Xiangyu Gao, Ke Ji, Yongning Jia, et al.
Investigational New Drugs
|
October 14, 2020
A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer
Jin-Ji Yang, Jian Fang, Yong-Qian Shu, et al.
Page
of 21
Search research articles
Search
Showing results (141-150 of 209) with videos related to
Sort By:
Page
of 21
Thoracic Cancer
|
August 19, 2023
Predicting pathological response to neoadjuvant or conversion chemoimmunotherapy in stage IB-III non-small cell lung cancer patients using radiomic features
Nong Yang, Hai-Lin Yue, Bai-Hua Zhang, et al.
JTO Clinical and Research Reports
|
October 11, 2022
Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring <i>MET</i> Exon 14 Skipping Alterations
Shun Lu, Jian Fang, Xingya Li, et al.
The Oncologist
|
April 17, 2026
Characterization and Clinical Management of Adverse Events Following Treatment with Repotrectinib: A TRIDENT-1 Analysis
Alexander Drilon, Byoung Chul Cho, D Ross Camidge, et al.
The Oncologist
|
May 8, 2026
Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis
Alexander Drilon, Byoung Chul Cho, D Ross Camidge, et al.
The Lancet. Respiratory Medicine
|
June 24, 2021
Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study
Shun Lu, Jian Fang, Xingya Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 5, 2025
Quantitative and Dynamic ctDNA as a Biomarker of Response and Survival in Patients With Advanced Lung Squamous Cell Carcinoma Receiving Immunochemotherapy or Chemotherapy Alone
Fei Zhou, Jiao Zhang, Shengxiang Ren, et al.
International Journal of Cancer
|
September 19, 2022
First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis
Tianshu Liu, Yuxian Bai, Xiaoyan Lin, et al.
Chinese Medical Journal
|
February 19, 2025
Potential utility of albumin-bilirubin and body mass index-based logistic model to predict survival outcome in non-small cell lung cancer with liver metastasis treated with immune checkpoint inhibitors
Lianxi Song, Qinqin Xu, Ting Zhong, et al.
Nature Medicine
|
May 22, 2024
Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial
Xiangyu Gao, Ke Ji, Yongning Jia, et al.
Investigational New Drugs
|
October 14, 2020
A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer
Jin-Ji Yang, Jian Fang, Yong-Qian Shu, et al.
Page
of 21